Literature DB >> 21084867

Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.

Abhik Saha1, Rajeev Kaul, Masanao Murakami, Erle S Robertson.   

Abstract

Tumor viruses have provided relatively simple genetic systems, which can be manipulated for understanding the molecular mechanisms of the cellular transformation process. A growing body of information in the tumor virology field provides several prospects for rationally targeted therapies. However, further research is needed to better understand the multiple mechanisms utilized by these viruses in cancer progression in order to develop therapeutic strategies. Initially viruses were believed to be associated with cancers as causative agents only in animals. It was almost half a century before the first human tumor virus, Epstein-Barr virus (EBV), was identified in 1964. Subsequently, several human tumor viruses have been identified including Kaposi sarcoma associated herpesvirus (KSHV), human Papillomaviruses (HPV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T lymphotropic virus (HTLV-1) and recently identified Merkel cell Polyomavirus (MCPyV). Tumor viruses are sub-categorized as either DNA viruses, which include EBV, KSHV, HPV, HBV, and MCPyV, or RNA viruses such as HCV and HTLV-1. Tumor-viruses induce oncogenesis through manipulating an array of different cellular pathways. These viruses initiate a series of cellular events, which lead to immortalization and proliferation of the infected cells by disrupting the mitotic checkpoint upon infection of the host cell. This is often accomplished by functional inhibition or proteasomal degradation of many tumor suppressor proteins by virally encoded gene products. The virally infected cells can either be eliminated via cell-mediated apoptosis or persist in a state of chronic infection. Importantly, the chronic persistence of infection by tumor viruses can lead to oncogenesis. This review discusses the major human tumor associated viruses and their ability to modulate numerous cell signaling pathways, which can be targeted for potential therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084867      PMCID: PMC5965687          DOI: 10.4161/cbt.10.10.13923

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  200 in total

Review 1.  Cell cycle control as a basis for cancer drug development (Review).

Authors:  E R McDonald; W S El-Deiry
Journal:  Int J Oncol       Date:  2000-05       Impact factor: 5.650

Review 2.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

3.  COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.

Authors:  Tonia L Symensma; DeeAnn Martinez-Guzman; Qingmei Jia; Eric Bortz; Ting-Ting Wu; Nandini Rudra-Ganguly; Steve Cole; Harvey Herschman; Ren Sun
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

Review 5.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 6.  VHL and p53: tumor suppressors team up to prevent cancer.

Authors:  Gregg L Semenza
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

Review 7.  The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.

Authors:  Marianne Farnebo; Vladimir J N Bykov; Klas G Wiman
Journal:  Biochem Biophys Res Commun       Date:  2010-05-21       Impact factor: 3.575

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  Regulation of transcription by the Epstein-Barr virus nuclear antigen EBNA 2.

Authors:  Richard D Palermo; Helen M Webb; Andrea Gunnell; Michelle J West
Journal:  Biochem Soc Trans       Date:  2008-08       Impact factor: 5.407

10.  Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.

Authors:  M Persico; M Capasso; R Russo; E Persico; L Crocè; C Tiribelli; A Iolascon
Journal:  Gut       Date:  2007-09-19       Impact factor: 23.059

View more
  45 in total

1.  B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.

Authors:  Siva Koganti; Amanda de la Paz; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

Review 2.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

3.  Role of stromal-epithelial interaction in the formation and development of cancer cells.

Authors:  Viktor Shtilbans
Journal:  Cancer Microenviron       Date:  2013-02-22

4.  STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation.

Authors:  Siva Koganti; Joyce Hui-Yuen; Shane McAllister; Benjamin Gardner; Friedrich Grasser; Umaimainthan Palendira; Stuart G Tangye; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

Review 5.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

6.  Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer.

Authors:  Ala-Eddin Al Moustafa; Noor Al-Antary; Tahar Aboulkassim; Nizar Akil; Gerald Batist; Amber Yasmeen
Journal:  Hum Vaccin Immunother       Date:  2016-04-15       Impact factor: 3.452

7.  Increased risk of cancer after Bell's palsy: a 5-year follow-up study.

Authors:  Jau-Jiuan Sheu; Joseph J Keller; Herng-Ching Lin
Journal:  J Neurooncol       Date:  2012-08-14       Impact factor: 4.130

Review 8.  Pathogen-driven cancers and emerging immune therapeutic strategies.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

9.  Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.

Authors:  Xiaojie Xu; Zhongyi Fan; Lei Kang; Juqiang Han; Chengying Jiang; Xiaofei Zheng; Ziman Zhu; Huabo Jiao; Jing Lin; Kai Jiang; Lihua Ding; Hao Zhang; Long Cheng; Hanjiang Fu; Yi Song; Ying Jiang; Jiahong Liu; Rongfu Wang; Nan Du; Qinong Ye
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection.

Authors:  Abhik Saha; Hem C Jha; Santosh K Upadhyay; Erle S Robertson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.